Antonio Passaro, MD, PhD is a medical oncologist at the Division of Thoracic Oncology of the European Institute of Oncology in Milan, Italy. He received the PhD in molecular medicine with a thesis on lung cancer.
He is a clinician and translational researcher specialized in lung cancer. His main areas or research and clinical interest are predictive biomarker, in particular EGFR, and related target and immunotherapy agents, from discovery to validation in clinical setting. He is also strongly involved and interested in using target agents in non-metastatic setting, alone or in multimodality approach for early or locally-advanced disease.
Dr Passaro is involved in a portfolio of many clinical trials, sponsored and academic, investigating new anticancer agents.
He is currently a Member of the ESMO Council, Chair of the Press & Media Affairs Committee, and a member of the social media working group and ESMO-MCBS working group. He is currently a member of the ESMO Lung Cancer Faculty, and member of the 2020 Scientific Committee for the ESMO SARS-CoV-2 and cancer track. He is also an AIOM (Italian Association of Medical Oncology) board member for lung cancer guidelines.
Author of several peer-reviewed manuscripts, he serves on the Editorial Board of different clinical cancer journals, and acts as reviewer for multiple lung cancer publications.
Last update: February 2021